Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | CAR-T therapy for aggressive B-cell lymphomas

Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third-line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).